• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

实用临床试验设计比较炎症性肠病不同治疗方法的真实世界疗效:PRACTICE-IBD 欧洲共识。

Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus.

机构信息

Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy; Gastroenterology Unit, Azienda Ospedaliero-Universitaria di Cagliari,Italy.

IBD Unit, Department of Gastroenterology and Digestive Endoscopy, San Camillo-Forlanini, Rome, Italy; Department of Gastroenterology and Digestive Endoscopy, San Raffaele Hospital and Vita-Salute San Raffaele Hospital, Milan, Italy.

出版信息

J Crohns Colitis. 2024 Aug 14;18(8):1222-1231. doi: 10.1093/ecco-jcc/jjae026.

DOI:10.1093/ecco-jcc/jjae026
PMID:
38367197
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11324339/
Abstract

BACKGROUND AND AIMS

Pragmatic studies designed to test interventions in everyday clinical settings can successfully complement the evidence from registration and explanatory clinical trials. The European consensus project PRACTICE-IBD was developed to identify essential criteria and address key methodological issues needed to design valid, comparative, pragmatic studies in inflammatory bowel diseases [BDs].

METHODS

Statements were issued by a panel of 11 European experts in IBD management and trial methodology, on four main topics: [I] study design; [II] eligibility, recruitment and organisation, flexibility; [III] outcomes; [IV] analysis. The consensus process followed a modified Delphi approach, involving two rounds of assessment and rating of the level of agreement [1 to 9; cut-off ≥7 for approval] with the statements by 18 additional European experts in IBD.

RESULTS

At the first voting round, 25 out of the 26 statements reached a mean score ≥7. Following the discussion that preceded the second round of voting, it was decided to eliminate two statements and to split one into two. At the second voting round, 25 final statements were approved: seven for study design; six for eligibility, recruitment and organisation, flexibility; eight for outcomes; and four for analysis.

CONCLUSIONS

Pragmatic, randomised, clinical trials can address important questions in IBD clinical practice, and may provide complementary, high-level evidence, as long as they follow a methodologically rigorous approach. These 25 statements intend to offer practical guidance in the design of high-quality, pragmatic, clinical trials that can aid decision making in choosing a management strategy for IBDs.

摘要

背景与目的

旨在检验日常临床环境下干预措施的实用性研究,可以成功补充注册和解释性临床试验的证据。欧洲共识项目 PRACTICE-IBD 旨在确定设计有效的、具有可比性的、实用性炎症性肠病(IBD)研究所需的基本标准和解决关键方法学问题。

方法

IBD 管理和试验方法学的 11 位欧洲专家小组就四个主要主题发布了声明:[I]研究设计;[II]合格性、招募和组织、灵活性;[III]结局;[IV]分析。共识过程遵循改良 Delphi 方法,包括两轮评估和对 18 位额外的 IBD 欧洲专家对声明的一致性程度(1 到 9;≥7 为批准)进行评分。

结果

在第一轮投票中,26 项声明中有 25 项得分为≥7。在第二轮投票前的讨论之后,决定删除两项声明,并将一项声明分为两项。在第二轮投票中,批准了 25 项最终声明:7 项用于研究设计;6 项用于合格性、招募和组织、灵活性;8 项用于结局;4 项用于分析。

结论

实用性、随机对照临床试验可以解决 IBD 临床实践中的重要问题,并可以提供补充性的高水平证据,只要它们遵循严格的方法学方法。这 25 项声明旨在为高质量、实用性临床试验的设计提供实用指导,以帮助在选择 IBD 管理策略时做出决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2d8/11324339/3937d7feb882/jjae026_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2d8/11324339/3937d7feb882/jjae026_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2d8/11324339/3937d7feb882/jjae026_fig1.jpg

相似文献

1
Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus.实用临床试验设计比较炎症性肠病不同治疗方法的真实世界疗效:PRACTICE-IBD 欧洲共识。
J Crohns Colitis. 2024 Aug 14;18(8):1222-1231. doi: 10.1093/ecco-jcc/jjae026.
2
[Pan American Crohn's and Colitis Organization (PANCCO) and the Interamerican Society of Endoscopy (SIED) consensus on endoscopy in inflammatory bowel disease].[泛美克罗恩病和结肠炎组织(PANCCO)与美洲内镜学会(SIED)关于炎症性肠病内镜检查的共识]
Rev Gastroenterol Peru. 2024 Apr-Jun;44(2):179-215.
3
British Dietetic Association consensus guidelines on the nutritional assessment and dietary management of patients with inflammatory bowel disease.英国营养协会关于炎症性肠病患者营养评估和饮食管理的共识指南。
J Hum Nutr Diet. 2023 Feb;36(1):336-377. doi: 10.1111/jhn.13054. Epub 2022 Jul 21.
4
Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding.澳大利亚炎症性肠病共识声明:关于备孕、妊娠和哺乳。
Gut. 2023 Jun;72(6):1040-1053. doi: 10.1136/gutjnl-2022-329304. Epub 2023 Mar 21.
5
Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts.炎症性肠病和脊柱关节炎共存患者的多学科管理:意大利专家的德尔菲共识。
Dig Liver Dis. 2017 Dec;49(12):1298-1305. doi: 10.1016/j.dld.2017.06.004. Epub 2017 Jun 23.
6
Multidisciplinary Decision-Making-ITAlian Consensus After Two Years of Real Practice on the Management of Severe Uncontrolled CRSwNP by Biologics (ITACA Study).多学科决策——生物制剂治疗重度未控制 CRSwNP 管理的两年真实实践后的 ITALIAN 共识(ITACA 研究)。
Curr Allergy Asthma Rep. 2024 Mar;24(3):143-154. doi: 10.1007/s11882-024-01135-z. Epub 2024 Mar 12.
7
Criteria for Critical Care Infants and Children: PICU Admission, Discharge, and Triage Practice Statement and Levels of Care Guidance.危重症婴幼儿标准:PICU 收治、出院和分诊实施声明和分级护理指南。
Pediatr Crit Care Med. 2019 Sep;20(9):847-887. doi: 10.1097/PCC.0000000000001963.
8
Developing a framework for the ethical design and conduct of pragmatic trials in healthcare: a mixed methods research protocol.制定医疗保健中实用临床试验的伦理设计和实施框架:混合方法研究方案。
Trials. 2018 Sep 27;19(1):525. doi: 10.1186/s13063-018-2895-x.
9
Pediatric to Adult Transition in Inflammatory Bowel Disease: Consensus Guidelines for Australia and New Zealand.炎症性肠病从儿科到成人的过渡:澳大利亚和新西兰共识指南
Inflamm Bowel Dis. 2025 Feb 6;31(2):563-578. doi: 10.1093/ibd/izae087.
10
The knowledge and skills needed to perform intestinal ultrasound for inflammatory bowel diseases-an international Delphi consensus survey.执行炎症性肠病肠道超声所需的知识和技能:国际德尔菲共识调查。
Aliment Pharmacol Ther. 2022 Jul;56(2):263-270. doi: 10.1111/apt.16950. Epub 2022 Apr 29.

引用本文的文献

1
Incorporating Real-World Variability in Clinical IBD Research.在炎症性肠病临床研究中纳入真实世界的变异性
J Eval Clin Pract. 2025 Jun;31(4):e70117. doi: 10.1111/jep.70117.
2
Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease.解读炎症性肠病医学治疗的现代随机对照试验。
Nat Rev Gastroenterol Hepatol. 2024 Nov;21(11):792-808. doi: 10.1038/s41575-024-00989-y. Epub 2024 Oct 8.

本文引用的文献

1
Learning From the Success of the ACTIV Platform.从ACTIV平台的成功中学习。
JAMA. 2023 Dec 26;330(24):2363-2364. doi: 10.1001/jama.2023.24087.
2
An overview of methodological considerations regarding adaptive stopping, arm dropping, and randomization in clinical trials.关于临床试验中适应性停止、组间剔除和随机化的方法学考量概述。
J Clin Epidemiol. 2023 Jan;153:45-54. doi: 10.1016/j.jclinepi.2022.11.002. Epub 2022 Nov 17.
3
Adjustment for Baseline Characteristics in Randomized Clinical Trials.随机临床试验中基线特征的调整
JAMA. 2022 Dec 6;328(21):2155-2156. doi: 10.1001/jama.2022.21506.
4
New and Emerging Treatments for Inflammatory Bowel Disease.炎症性肠病的新型及新兴治疗方法
Digestion. 2023;104(1):74-81. doi: 10.1159/000527422. Epub 2022 Nov 10.
5
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.乌司奴单抗治疗克罗恩病的长期真实世界疗效和安全性:SUSTAIN 研究。
Inflamm Bowel Dis. 2022 Nov 2;28(11):1725-1736. doi: 10.1093/ibd/izab357.
6
How to Use and Interpret the Results of a Platform Trial: Users' Guide to the Medical Literature.如何使用和解释平台试验的结果:医学文献用户指南。
JAMA. 2022 Jan 4;327(1):67-74. doi: 10.1001/jama.2021.22507.
7
Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval.利用真实世界数据模拟获得美国食品和药物管理局加速批准的治疗药物的上市后确证性临床试验的可行性。
JAMA Netw Open. 2021 Nov 1;4(11):e2133667. doi: 10.1001/jamanetworkopen.2021.33667.
8
Emulation of a randomized controlled trial in ulcerative colitis with US and French claims data: Infliximab with thiopurines compared to infliximab monotherapy.利用美国和法国的索赔数据模拟溃疡性结肠炎的随机对照试验:硫唑嘌呤联合英夫利昔单抗与英夫利昔单抗单药治疗比较。
Pharmacoepidemiol Drug Saf. 2022 Feb;31(2):167-175. doi: 10.1002/pds.5356. Epub 2021 Sep 26.
9
Calibrating Real-World Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Crohn's Disease.校准真实世界证据研究与随机试验:英夫利昔单抗治疗克罗恩病的疗效。
Clin Pharmacol Ther. 2022 Jan;111(1):179-186. doi: 10.1002/cpt.2304. Epub 2021 Jun 14.
10
Breaking the therapeutic ceiling in drug development in ulcerative colitis.在溃疡性结肠炎的药物研发中突破治疗上限。
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):589-595. doi: 10.1016/S2468-1253(21)00065-0. Epub 2021 May 19.